Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hee-Jeong | - |
dc.contributor.author | Kim, Ji-Yeon | - |
dc.contributor.author | Lee, Young | - |
dc.contributor.author | Kim, Jung Mogg | - |
dc.contributor.author | Kim, Young Bong | - |
dc.contributor.author | Chun, Taehoon | - |
dc.contributor.author | Oh, Yu-Kyoung | - |
dc.date.accessioned | 2021-09-08T04:28:55Z | - |
dc.date.available | 2021-09-08T04:28:55Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-03-19 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116790 | - |
dc.description.abstract | Needle-free nonparenteral vaccines offer a number of practical advantages, especially in developing countries. To address the effects of vaccine administration route, we tested mucosal and systemic immune responses against human papillomavirus 16 L1(HPV16L1) protein using intranasal, intravaginal, transdermal, sublingual (SL) and intramuscular routes. The SL route provided the most effective mucosal secretory IgA (sIgA) and serum IgG responses. After a 15014 antigen dose via the SL route, saliva sIgA levels were 7.2- and 5.8-fold higher than those achieved via intravaginal and transdermal routes, respectively. Notably, SL administration even produced 4.6-fold higher levels of vaginal sIgA levels than did intravaginal delivery of 150 mu g antigen. To enhance the immunogenicity of SL vaccines, we tested the adjuvanticity of nine molecules: three toll-like receptor agonists, three nucleotide-binding oligomerization-domain agonists, vitamin D3, poly-gamma-glutamic acid and cholera toxin subunit B (CTB). Among the molecules tested, CTB provided the most enhanced mucosal sIgA and systemic IgG induction. SL-applied CTB enhanced the production of interleukin-4 and interferon-gamma from stimulated CD4+ T cells. Moreover, interferon-gamma-producing CD8+ T cell responses were increased 1.7-fold after co-treatment with SL CTB and HPV16L1. These results suggest the potential of the SL route for delivery of HPV16L1 vaccines using CTB as an adjuvant. (C) 2010 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | TOXIN B-SUBUNIT | - |
dc.subject | POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES | - |
dc.subject | CHOLERA-TOXIN | - |
dc.subject | MUCOSAL ADJUVANTS | - |
dc.subject | ORAL IMMUNIZATION | - |
dc.subject | DENDRITIC CELLS | - |
dc.subject | IGE ANTIBODY | - |
dc.subject | VACCINATION | - |
dc.subject | DELIVERY | - |
dc.subject | MICE | - |
dc.title | Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chun, Taehoon | - |
dc.identifier.doi | 10.1016/j.vaccine.2010.01.013 | - |
dc.identifier.scopusid | 2-s2.0-77649179585 | - |
dc.identifier.wosid | 000276505700004 | - |
dc.identifier.bibliographicCitation | VACCINE, v.28, no.14, pp.2598 - 2606 | - |
dc.relation.isPartOf | VACCINE | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 28 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 2598 | - |
dc.citation.endPage | 2606 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | TOXIN B-SUBUNIT | - |
dc.subject.keywordPlus | POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES | - |
dc.subject.keywordPlus | CHOLERA-TOXIN | - |
dc.subject.keywordPlus | MUCOSAL ADJUVANTS | - |
dc.subject.keywordPlus | ORAL IMMUNIZATION | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | IGE ANTIBODY | - |
dc.subject.keywordPlus | VACCINATION | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordAuthor | Sublingual route | - |
dc.subject.keywordAuthor | Mucosal vaccination | - |
dc.subject.keywordAuthor | Human papillomavirus | - |
dc.subject.keywordAuthor | Sublingual adjuvant | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.